Active, not recruitingPhase 4NCT07275060

Immunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 vs. 8 Weeks Apart

Studying Avian influenza

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Canadian Immunization Research Network
Principal Investigator
Joanne M Langley, PhD
CIRN, Canadian Center for Vaccinology, Dalhousie University
Intervention
H5N1 vaccine (Arepanrix)(biological)
Enrollment
312 enrolled
Eligibility
18-59 years · All sexes
Timeline
2025 – 2027

Study locations (4)

Collaborators

Dalhousie University · IWK Health Centre · Public Health Agency of Canada (PHAC) · Canadian Center for Vaccinology · CHU de Quebec-Universite Laval · Vaccine Evaluation Center, Canada · McGill University Health Centre/Research Institute of the McGill University Health Centre

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07275060 on ClinicalTrials.gov

Other trials for Avian influenza

Additional recruiting or active studies for the same condition.

See all trials for Avian influenza →

← Back to all trials